Tom Riga

Mr. Riga joined Chimerix in November 2023 with over 25 years of leadership experience. Prior to joining Chimerix, he was the President and Chief Executive Officer at Spectrum Pharmaceuticals from January 2022 through its acquisition in July 2023. In addition, he served as Chief Commercial Officer for nine years and Chief Operating Officer for five years. Before joining Spectrum, he led multiple oncology product teams holding commercial sales and marketing leadership positions at Dendreon, Amgen and Eli Lilly and Company. He began his career at Wyeth Ayerst Laboratories in pharmaceutical manufacturing. His diverse experience has integrated leadership and strategy to create meaningful value throughout his career.

Mr. Riga has been directly responsible for the successful commercialization of multiple oncology launches, consistently producing top-tier results. His commercial launch experience includes rare diseases, therapeutic and supportive care oncology.

Additionally, Mr. Riga has significant corporate and business development experience. He has executed deals including in-licensing and out-licensing assets, academic IP, and strategic M&A. He has led over $1 billion dollars of business development transactions across the healthcare space both domestically and internationally.

He holds a B.S. in Biology and Chemistry from St. Lawrence University and is an accredited public company director from UCLA’s Anderson School of Business.

Categorised in:

This post was written by tbe_admin